What Imizol Treats: Main Uses and Benefits

Imidocarb is commonly used for managing the acute phase of Babesiosis (piroplasmosis) and Anaplasmosis, which are significant tick-borne diseases in livestock and companion animals. This application is relevant in clinical settings marked by heightened physiological stress, as the treatment is applied in addressing the parasitic cause of systemic febrile distress and severe anemia. The agent is utilized across multiple species, including cattle and sheep, for these specific therapeutic contexts.

The medicine's relevance spans primary indications, including the acute forms of Babesiosis and Anaplasmosis, and is considered relevant for managing the persistent carrier state of infection in asymptomatic animals.

---

“It is considered relevant support, and supports general well-being during symptomatic phases when symptoms from blood parasites are more noticeable, especially in endemic areas.”

---

Beyond acute relief, Imidocarb supports the management of the infection source, contributing to easing the overall symptom load. It is also applied to help prevent the clinical expression of disease (chemoprophylaxis) when animals are moved into high-risk, endemic regions. The core benefit is that the treatment provides support that helps ease the overall symptom burden and helps improve day-to-day comfort during symptomatic periods.

---

Quick Fact: Support for Symptoms Related to Systemic Imbalance This medication is often used during phases when symptoms become more noticeable, and helps address symptom clusters that may become intense or disruptive, such as high fever and generalized malaise associated with acute parasitic blood infection.

Who Can and Cannot Use Imizol?

The eligibility for Imizol (Imidocarb dipropionate) is strictly defined by its status as a specialized veterinary product. Regulatory documents determine the target species and specific contraindications that restrict its use.

---

Populations Allowed and Contraindicated

Classification	Eligibility Rule (Based on Official Labeling)
Target Species	Approved for use in Cattle, Dogs, Horses, and Sheep for specific indications.
Absolute Contraindication	The product is NOT FOR HUMAN USE and is contraindicated in animals with known hypersensitivity to the active ingredient.
Toxic Interaction Risk	Use is prohibited in animals exposed to cholinesterase-inhibiting drugs, pesticides, or chemicals.

---

Conditional Use and Restrictions

Use is subject to conditional restrictions in certain groups, as safety has not been fully established. The safety and effectiveness of Imizol have not been determined in puppies or in breeding, pregnant, or lactating dogs. Furthermore, the drug MUST NOT BE ADMINISTERED INTRAVENOUSLY in any approved species. Vets must exercise caution when administering the drug to debilitated animals or those with impaired lung, liver, or kidney function.

Interactions with other medicines and products

Official Interaction Statements

The regulatory profile for Imidocarb is characterized by a critical pharmacodynamic interaction and specific pharmaceutical constraints documented in government labeling, such as the FDA Prescribing Information and European Summary of Product Characteristics (SmPC).

Contraindicated Co-administration:

Co-administration with cholinesterase-inhibiting drugs, pesticides, or chemicals is formally prohibited. This restriction is based on the additive anticholinesterase activity of the substances, which could lead to intensified adverse cholinergic signs.

Interaction Type	Interacting Agent	Official Constraint
Pharmacodynamic	Cholinesterase Inhibitors (e.g., organophosphates)	Contraindicated for simultaneous use.
Pharmaceutical	Other Medicinal Products	Must not be mixed in the same syringe or container.

Other Interactions

Official regulatory documents do not specify clinically significant interactions involving metabolic pathways, such as those mediated by cytochrome P450 (CYP) enzymes. Similarly, there are no documented interactions with food, alcohol, or herbal products. The primary restriction remains the prohibition against simultaneous use with any cholinesterase-inhibiting agent.

The specialized action of Imidocarb is defined by a dual-targeting mechanism that rapidly and selectively disrupts the core survival processes of the protozoal organism, leading to its effective clearance from the bloodstream.

---

Dual Blockade of Parasite Proliferation and Energy

This core mechanistic domain involves two simultaneous inhibitory actions. Imidocarb functions by inhibiting key enzymes, such as Topoisomerase II, leading to the suppression of kinetoplast DNA replication within the parasite. Concurrently, the molecule imposes a metabolic blockade on the parasite's glycolysis pathway, preventing it from generating necessary energy (ATP) from host glucose. This dual interference modifies the parasite's ability to complete its reproductive and metabolic processes.

---

Mechanistic Cascade Leading to Erythrocyte Protection

The simultaneous failure of DNA synthesis and energy metabolism rapidly triggers cellular destruction (lysis) of the protozoal organisms circulating in the blood. The protozoacidal effect constitutes the mechanism's primary physiological action because it halts the parasitic life cycle, resulting in the cessation of erythrocyte invasion and lysis. The physiological consequence is the systemic maintenance of erythrocyte integrity by removing the parasitic trigger for lysis.

Imizol (imidocarb dipropionate) is a veterinary-only, prescription-only injectable solution, typically administered by a licensed veterinarian. This medication is not for human use. The drug is most often used for the treatment and prevention of tick-borne diseases such as babesiosis and anaplasmosis in target animal species like cattle, sheep, horses, and dogs, depending on the specific product formulation and regional approvals.

Administration and Dosage

Imizol must be administered via subcutaneous (SC) or intramuscular (IM) injection; intravenous (IV) administration is strictly prohibited. The specific dose of Imidocarb dipropionate (usually 120 mg/mL or 85 mg/mL) varies significantly based on the animal species, the condition being treated (treatment or prophylaxis), and the severity of the infection.

For example, the recommended dosage for dogs with babesiosis is often 6.6 mg/kg (3 mg/lb) body weight, typically repeated in two weeks for a total of two treatments, and is given either SC or IM. For cattle babesiosis treatment, a common dose is 1.0 mL per 100 kg body weight (for 85 mg/mL formulation), given subcutaneously as a single dose.

Target Species	Indication (Example)	Route	Dose (120 mg/mL formulation)
Dogs	Babesiosis Treatment	SC or IM	6.6 mg/kg (repeated in 2 weeks)
Cattle	Babesiosis Treatment	SC	1.0 mL/100 kg body weight
Cattle	Anaplasmosis Treatment	SC	2.5 mL/100 kg body weight

It is crucial that the animal’s weight is determined accurately and that the recommended dose is not exceeded to avoid adverse effects. The administration should be performed only under the direct order and supervision of a licensed veterinarian. Do not use Imizol simultaneously with cholinesterase-inhibiting drugs or pesticides, and exercise caution in animals with impaired kidney, liver, or lung function.

Research Evidence / Overview of Studies for Imidocarb (Imizol)

---

Evidence for Addressing Acute Babesiosis (Piroplasmosis)

Research examining Imidocarb for the acute phase of Babesiosis often involves controlled clinical trials and field studies, and was used in research exploring how symptoms change over time in different animal species. Outcomes that researchers focused on included measuring systemic and functional imbalance, such as fever, and monitoring physiological strain by tracking hematological parameters, like red blood cell counts.

The findings describe patterns observed in the studies related to the timeline of symptom abatement and the modification of blood cell counts following administration. Research highlights changes measured during the study period, primarily related to red blood cell status.

What remains uncertain is the need for more comparative research against all currently available alternative agents. Also, the long-term outcomes and overall persistence of measured outcomes across all geographical strains of the parasite are not uniformly established in the broader evidence landscape.

---

Evidence for Addressing the Persistent Carrier State of Babesiosis

Imidocarb was studied for conditions characterized by persistent, non-symptomatic infection, where the goal of research is to investigate the potential for parasite non-detection. Research scenarios included highly specialized in vivo studies and long-term cohort monitoring. Researchers examined parasite clearance using highly sensitive methods like specialized laboratory tests or bioassays, and studies explored the reduction of transmission indicators.

Studies monitored and reported parasite non-detection in some species/parasite combinations, with findings indicating patterns of parasite non-detection following treatment, which was confirmed by specific laboratory tests.

Certainty remains low for certain Babesia strains or co-infections, as some studies have reported mixed or inconsistent findings in achieving confirmed parasite non-detection. The methods used to define clearance across different studies are heterogeneous, and results apply only to the populations studied.

---

What Research Gaps and Uncertainty Remain

Evidence highlights what is known—and what is still uncertain—about this medicine. A primary limitation is the heterogeneity of the studies, and some findings were mixed, particularly when assessing the elimination of the carrier state for all parasite species.

There is limited information for long-term outcomes, as many published clinical trial summaries focus on short follow-up durations (e.g., 2–4 weeks). Comparative research against existing alternative agents is lacking in certain contexts. Finally, research does not determine whether an individual animal will respond similarly, reflecting the specific conditions under which the studies were conducted.

Key Studies & References DailyMed Label for Imidocarb Dipropionate Injectable Solution (Veterinary)

Common questions about Imizol (FAQ)

Q: What is Imizol?

Imizol (imidocarb dipropionate) is a veterinary medication primarily used to treat and prevent specific tick-borne diseases in animals, particularly cattle, horses, dogs, and sheep. It belongs to the class of carbanilide derivatives and works by interfering with the parasite's essential metabolic processes, leading to its death.

Q: How does Imizol work to treat infections?

Imizol, the brand name for imidocarb dipropionate, acts as an antiprotozoal agent. Its mechanism of action involves inhibiting nucleic acid synthesis within the protozoa (such as Babesia species). This inhibition disrupts the parasite's ability to replicate and function, effectively clearing the infection from the animal's bloodstream.

Q: What conditions is Imizol used to treat in animals?

Imizol is specifically indicated for the treatment and prophylaxis of babesiosis (piroplasmosis), a tick-borne disease caused by Babesia protozoa, in susceptible animal species like cattle, horses, and dogs. It is also sometimes used to treat anaplasmosis, another tick-borne illness, in cattle.

Q: Is Imizol available as a human medicine?

No, Imizol (imidocarb dipropionate) is not approved or manufactured for human use. It is strictly a veterinary medicine and should only be administered to animals under the direction of a veterinarian. There are alternative, approved treatments for human protozoal infections.

Q: What are the common side effects of Imizol in animals?

The most common side effects observed in animals after Imizol administration are related to its cholinergic effects, which may include:

• Salivation (excessive drooling)
• Tearing (lacrimation)
• Colic-like signs or mild abdominal discomfort
• Transient muscle tremors at the injection site

These side effects are usually temporary and often resolve on their own or with supportive care, such as the administration of atropine by a veterinarian.

Q: How is Imizol administered to animals?

Imizol is typically administered via subcutaneous or intramuscular injection by a trained veterinarian or veterinary technician. The route and exact dosage depend on the animal species, the specific condition being treated (treatment or prophylaxis), and the severity of the infection. It is not an oral medication.

Storage and Disposal Requirements for Imizol (Imidocarb Dipropionate)

This section outlines the official, label-based requirements for storing and disposing of Imizol injection.

---

Mandatory Storage Conditions

Imizol must be stored at or below 25 C (77 F), with regulatory allowances for temperature excursions up to 40 C (104 F). It is mandatory to protect the product from freezing to maintain its quality and stability.

Handling and Protection

The product must be stored in its original package to protect the solution from light. For safety, the medicine must be kept out of the reach and sight of children, as required by the official labeling.

Disposal Instructions

Disposal of any unused or expired Imizol must be performed in accordance with local requirements for pharmaceutical waste. The product should not contaminate surface water or ditches.